Qualigen Therapeutics, Inc.
QLGN
$1.97
$0.073.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 33.20K | -1.22M | 123.40K | 754.30K | 364.40K |
| Gross Profit | -33.20K | 1.22M | -123.40K | -754.30K | -364.40K |
| SG&A Expenses | 2.49M | 1.02M | 1.15M | 986.50K | 1.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.53M | 973.00K | 1.27M | 1.74M | 1.42M |
| Operating Income | -2.53M | -973.00K | -1.27M | -1.74M | -1.42M |
| Income Before Tax | -2.65M | -850.30K | -1.80M | -1.48M | -2.03M |
| Income Tax Expenses | 0.00 | 5.50K | -2.20K | -1.20K | 1.80K |
| Earnings from Continuing Operations | -2.65M | -855.80K | -1.79M | -1.48M | -2.03M |
| Earnings from Discontinued Operations | -- | 0.00 | -- | -100.00K | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.65M | -855.80K | -1.79M | -1.58M | -2.03M |
| EBIT | -2.53M | -973.00K | -1.27M | -1.74M | -1.42M |
| EBITDA | -- | -971.90K | -1.27M | -1.74M | -1.42M |
| EPS Basic | -1.82 | -1.09 | -4.70 | -10.37 | -17.60 |
| Normalized Basic EPS | -1.05 | -0.34 | -3.41 | -6.16 | -8.02 |
| EPS Diluted | -1.82 | -1.09 | -4.70 | -10.37 | -17.60 |
| Normalized Diluted EPS | -1.05 | -0.34 | -3.41 | -6.16 | -8.02 |
| Average Basic Shares Outstanding | 1.46M | 785.70K | 387.90K | 152.10K | 118.90K |
| Average Diluted Shares Outstanding | 1.46M | 785.70K | 387.90K | 152.10K | 118.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |